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The number of elderly patients with diffuse large B cell lymphoma (DLBCL) continues to increase but the data
regarding autologous stem cell transplantation (ASCT) for elderly patients are limited. We analyzed 484
patients, ages 60 years or over, diagnosed with relapsed/refractory DLBCL who received ASCT from 1993 to
2010 in the Japan Society for Hematopoietic Cell Transplantation database. Median age was 64 years (range,
60 to 78). To evaluate the impact of age at ASCT, patients were classiﬁed into 3 groups: those between the
ages of 60 to 64, 65 to 69, and 70 years or over. Overall nonrelapse mortality (NRM) at day 100, 1 year, and
2 years was 4.1%, 5.9% and 7.7%, respectively. NRM did not signiﬁcantly differ among age groups (P ¼ .60).
Two-year progression-free survival (PFS) and overall survival (OS) were 48% and 58%, respectively. PFS and OS
were signiﬁcantly longer in patients 60 to 64 years old; however, the survival rate was acceptable even in
those 70 or over, with a 2-year OS of 46%. ASCT is feasible in selected elderly patients and age alone should
not be a contraindication for ASCT. Eligibility should be individualized and identiﬁcation of a subset of elderly
patients at high risk of treatment-related morbidity or mortality warrants investigation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most com-
mon type of adult non-Hodgkin lymphoma, accounting for
25% to 35% of non-Hodgkin lymphoma cases in bothWestern
countries and Japan [1,2]. As demonstrated by the Interna-
tional Prognostic Index (IPI) Project, age greater than
60 years is a poor prognostic factor for survival [3]. However,
the median age of patients at diagnosis is older than
60 years; in particular, the reported median age in Japan, an
aging society, is 70 years [2]. The proportion of elderlyedgments on page 689.
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14.01.025patients with DLBCL continues to increase in line with the
overall increase in life expectancy [4].
Despite overall improvements in the treatment of DLBCL,
including the use of rituximab [5], approximately one third of
patients fail to achieve complete remission or they experi-
ence relapse. This remains a major cause of morbidity and
mortality [6]. The standard treatment of patients with
relapsed/refractory DLBCL is salvage chemotherapy followed
by high-dose chemotherapy (HDC) with autologous stem cell
transplantation (ASCT) [7,8]. Even in the rituximab era, ASCT
plays a role in improving the prognosis of patients with
relapsed DLBCL [9]. Advanced age remains common exclu-
sion criteria for this procedure, although studies have sug-
gested that age alone does not predict treatment-related
mortality or disease outcome [10]. Improvements in sup-
portive therapies, such as in antibiotics and the routine use ofTransplantation.
Table 1
Patient Characteristics
Characteristic Age
60-64 yr
Age
65-69 yr
Age  70 yr P
Value
Patients (no.) 271 174 39
Male 167 (62) 111 (64) 33 (85) .020
IPI at diagnosis .015
Low 48 (19) 15 (9) 3 (8)
Low-int 53 (21) 35 (21) 8 (21)
Int-high 79 (31) 62 (37) 21 (54)
High 72 (29) 54 (33) 7 (29)
B symptoms at diagnosis .012
None 199 (76) 108 (65) 32 (82)
Present 62 (24) 58 (35) 7 (18)
PS at transplantation .373
0-1 227 (89) 140 (84) 33 (87)
2-4 28 (11) 26 (16) 5 (13)
Time from diagnosis to ASCT .022
Within 1 yr 73 (28) 62 (36) 6 (15)
Over 1 yr 191 (72) 110 (64) 33 (85)
Date of ASCT .643
Before 2000 13 (5) 8 (5) 1 (3)
2000-2005 51 (19) 31 (18) 11 (28)
After 2006 207 (76) 135 (76) 27 (69)
Date of diagnosis .084
Before Aug. 2003 82 (30) 42 (24) 16 (41)
After Sep. 2003 189 (70) 132 (76) 23 (59)
High-dose regimen .026
MCEC based 89 (34) 47 (28) 9 (26)
MEAM based 68 (26) 45 (27) 2 (6)
LEED 33 (12) 29 (17) 10 (29)
Others 74 (28) 47 (28) 14 (40)
No. of prior regimens .002
1-2 65 (61) 41 (62) 1 (7)
3 23 (21) 11 (17) 5 (36)
4 19 (18) 14 (21) 8 (57)
Status at transplantation .274
CR 105 (40) 54 (32) 17 (44)
PR 72 (28) 48 (29) 7 (18)
Not in remission 84 (32) 66 (39) 15 (38)
IPI indicates International Prognostic Index; PS, performance status; ASCT,
autologous stem cell transplantation; CR, complete response; PR, partial
response; MCEC, ranimustine, carboplatin, etoposide, and cyclophospha-
mide; MEAM, ranimustine, etoposide, cytarabine, and melphalan; LEED,
cyclophosphamide, etoposide, melphalan, and dexamethasone.
Data presented are n (% of total evaluable) unless otherwise indicated.
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this procedure to decrease to less than 5%, and this decrease
in the mortality may beneﬁt, particularly, elderly patients.
The European Blood and Marrow Transplantation (EBMT)
registry recently reported the results of ASCT in patients with
DLBCL [11]. Although nonrelapse mortality (NRM) was
slightly higher in elderly patients ages 60 years or over than
in the younger group (age younger than 60), overall survival
(OS) after ASCT was 60% at 3 years, which appears to validate
the procedure in selected patients. This was the largest study
to evaluate the outcome of ASCT for elderly patients, albeit
23% of patients received ASCT as consolidation of ﬁrst-line
treatment, confounding evaluation of the good OS. More-
over, the median duration of follow-up was 14.5 months,
which appears relatively short in evaluating long-term
outcome, and the number of patients older than 70 years
was too small (only 13 patients) to elucidate the outcome in
this population.
Here, we evaluated the safety and long-term outcome of
ASCT in elderly patients with relapsed/refractory DLBCL.
PATIENTS AND METHODS
We retrospectively analyzed clinical data of the Transplant Registry
Uniﬁed Management Program (TRUMP), which is a registry database of the
Japan Society for Hematopoietic Cell Transplantation [12]. TRUMP collects
pretreatment patient characteristics and renews data on survival and dis-
ease status annually using follow-up forms.
Using these data, we identiﬁed patients, ages 60 years or over, whowere
treated with ASCT for relapsed/refractory status from April 1993 to
September 2010. We excluded patients with central nervous system
involvement at diagnosis and those who received ASCT as consolidation of
ﬁrst-line treatment. Patients were classiﬁed by age into 3 groups: ages 60 to
64, 65 to 69, and 70 years or over. IPI was scored from 0 to 5 by age greater
than 60 years, disease stage 3 or 4, performance status (PS) 2, serum lactate
dehydrogenase level higher than upper limit of normal range, and extranodal
involvement  2 [3]. Treatment response was evaluated based on the 1999
International Working Group Criteria [13]. HDC was classiﬁed into 4 groups;
namely, an MCEC regimen (ranimustine [200 mg/m2 on days 8 and 3],
carboplatin [300 mg/m2 from days 7 to 4], etoposide [500 mg/m2 from
days 6 to 4], and cyclophosphamide [50 mg/kg on days3 and 2]) [14];
MEAM regimen (ranimustine [300mg/m2 on day6], etoposide [200mg/m2
on day 5 to 2], cytarabine [200 mg/m2 twice daily on days5 to2], and
melphalan [140 mg/m2 on day 1]); LEED regimen (cyclophosphamide
[60 mg/kg on days 4 and 3], etoposide [250 mg/m2 twice daily from
days 4 to 2], melphalan [130 mg/m2 on day-1], and dexamethasone
[40 mg/body from days4 to1]) [15]; and others. Only 4 patients received
a regimen that included total body irradiation (TBI), and all were included in
the “others” group. Because the TRUMP data concerning rituximab were
incomplete, we addressed the impact of a rituximab-containing regimen in
ﬁrst-line treatment on later ASCT by categorizing diagnosis as before or after
September 2003, when rituximab was approved for DLBCL in Japan.
Statistical Analysis
The focus of this study was the assessment of feasibility and efﬁcacy of
ASCT in elderly patients with relapsed/refractory DLBCL. For this purpose,
early NRM, late NRM after ASCT, relapse rate, and OS after ASCT in elderly
patients who relapsed or were refractory to ﬁrst-line treatment were eval-
uated. Early NRM was deﬁned as death within 100 days after ASCT that was
unrelated to the disease, relapse, or progression, and late NRM was deﬁned
as death during continuous remission after day 100. Progression or relapse
after ASCT were deﬁned as competing events in calculating the cumulative
incidence of NRM using competing risk regression analysis [16]. Relapse rate
was also evaluated by competing risk regression analysis, with death
without relapse deﬁned as a competing risk. OS and progression-free sur-
vival (PFS; time from ASCT to disease progression, relapse, or death from any
cause) were calculated using the Kaplan-Meier method [17] and compared
between groups by the log-rank test. Patient characteristics, including age
group, sex, IPI status at diagnosis, PS at ASCT, time from diagnosis to ASCT,
date of ASCT, date of diagnosis (before or after September 2003, the date of
rituximab approval for DLBCL in Japan), type of HDC regimen, number of
prior regimens, and response status at ASCT, were analyzed for their asso-
ciationwith OS or PFS by hazard ratio (HR) using a Cox proportional hazards
model [18]. Multivariate analysis was done by a stepwise method using
threshold values for removal from and addition to the model at P ¼ .10 andP ¼ .05, respectively. Descriptive analysis of categorical data was done using
the Fisher exact test. All analyses were performed using STATA version 11.0
(College Station, TX).RESULTS
Patient Characteristics
A total of 484 patients ages 60 years or older and diagnosed
with DLBCL received ASCT after status assignment as relapsed
or refractory during the study period. Patient characteristics
and transplantations in the study population are summarized
by age in Table 1. The median age of patients was 64 years
(range, 60 to 78). According to the age group, 271 patients
(56%) were ages 60 to 64 years, 174 patients (36%) were ages
65 to 69 years, and 39 patients (8%) were ages 70 years or
older at the time of ASCT. Median follow-up duration of sur-
viving patients after ASCT was 26.5 months. Although the
median follow-up duration does not exceed 3 years, we also
report the 3-year outcome for the comparison with the pre-
vious EBMT study. Median time from diagnosis to ASCT was
18.2 months and median number of prior chemotherapy
regimens before ASCT was 3 (range, 1 to 15). Approximately
65% of patients had an intermediate-high or high IPI risk at
diagnosis, and 35% were not in remission at ASCT (Table 1).
Signiﬁcant differences in patient characteristics among age
Figure 1. (A) Overall nonrelapse mortality and (B) nonrelapse mortality by age group.
Figure 2. Relapse rate by age group.
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diagnosis, time from diagnosis to ASCT, type of high-dose
regimen, and number of prior regimens.
Early and Late Nonrelapse Mortality
At the time of last follow-up, 173 of 484 patients (36%) had
died of DLBCL. Forty-nine patients (10%) died of causes unre-
lated to DLBCL, among whom 20 died within 100 days after
ASCT. Themajor cause of early NRMwas infection (11 patients,
55%), followed by multiorgan failure (5 patients, 25%) and
interstitial pneumonia (3patients,15%). Themajor cause of late
NRM (after day 100) was secondary malignancy (7 patients,
25%), followed by interstitial pneumonia (5 patients, 18%),
infection (4 patients, 14%), and hemorrhage (4 patients, 14%).
Overall NRM was 4.1% (95% conﬁdence interval [CI], 2.6% to
6.2%) at100days afterASCT, 5.9% (95%CI, 4.0% to8.3%) at1year,
7.7% (95% CI, 5.5% to 10.4%) at 2 years, and 10.7% (95%CI, 7.9% to
14.0%) at 3 years (Figure 1). Although early NRM was slightly
higher inpatients65yearsoldorolder,nosigniﬁcantdifference
in NRM was observed among patients 60 to 64 years, 65 to
69 years, and 70 years or older (Figure 1) (P¼ .60; NRM at day
100, 2.9% versus 5.7% versus 5.2%; NRM at 1 year, 4.9% versus
7.5%versus5.2%;NRMat3years,10.4%versus11.5%versus9.1%,
respectively). On univariate analysis, the presence of a B
symptomatdiagnosiswastheonlysigniﬁcantpatient factor for
the risk of NRM (HR, 1.85; 95% CI, 1.02 to 3.36; P ¼ .04). A
signiﬁcantlyhigherproportionof elderlypatients ages70years
orolder receiveda LEEDregimenthan thoseagedyounger than
70 (Table 1) (ages < 70, 14.4%;  70, 28.6%; P ¼ .03), and the
LEEDregimenwasassociatedwitha lowerriskofNRMthanthe
other regimens (HR, .24; 95% CI, .06 to 1.00; P ¼ .05). On
multivariate analysis, we found no signiﬁcant factors for the
risk of NRM, including age group.
Relapse Rate
The cumulative risk of relapse at 1 year, 2 years, and
3 years was 38.8% (95% CI, 34.3% to 43.3%), 45.5% (95% CI,
40.7% to 50.2%), and 47.7% (95% CI, 42.7 to 52.4%), respec-
tively. A signiﬁcant difference in relapse risk was seen among
age groups (Figure 2) (P¼ .01). Multivariate analysis revealed
the following 3 independent risk factors associated with
relapse risk: age 70 years or older (HR, 2.04; 95% CI, 1.20 to
3.48; P¼ .01), PS 2 to 4 at ASCT (HR, 1.54; 95% CI, 1.00 to 2.38;
P ¼ .05), and not in remission at transplantation (HR, 2.80;
95% CI, 1.98 to 3.951; P < .01).Survival after ASCT
One-year, 2-year, and 3-year PFS of all patients after ASCT
were 55.9% (95% CI, 51.2% to 60.3%), 47.7% (95% CI, 42.9% to
52.4%), and 40.6% (95% CI, 35.5% to 45.6%), respectively
(Figure 3). Two-year PFS of patients ages 60 to 64, 65 to 69,
and 70 years or older was 53.3% (95% CI, 46.7% to 59.5%),
40.7% (95% CI, 33.0% to 48.3%), and 41.5% (95% CI, 24.8% to
57.3%), respectively. Results of univariate and multivariate
analysis for the risk factors of PFS are summarized in Table 2.
Multivariate analysis revealed 3 independent risk factors
associated with shorter PFS: 65 years of age or older, PS 2 to 4
at ASCT, and response status at ASCT (Table 2).
One-year, 2-year, and 3-year OS of all patients after ASCT
were 69.7% (95% CI, 65.2 to 73.7%), 57.9% (95% CI, 53.0 to
62.5%) and 49.6% (95% CI, 44.3 to 54.7%), respectively
(Figure 3). Two-year OS of patients ages 60 to 64, 65 to 69,
and 70 years or older was 64.6% (95% CI, 58.0% to 70.5%),
50.6% (95% CI, 42.5% to 58.2%), and 45.7% (95% CI, 28.8% to
61.1%), respectively, and signiﬁcantly better in patients ages
60 to 64 years (P ¼ .01) (Figure 4). Patients who were not in
remission before ASCT showed signiﬁcantly shorter survival
than thosewho responded to treatment before ASCT (P< .01)
(Figure 4), but even among those who were not in remission
at ASCT, 2-year OS was 41.6% (95% CI, 33.4% to 49.5%). Results
of univariate and multivariate analysis are summarized in
Figure 3. (A) Progression-free survival and (B) overall survival.
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factors associated with shorter OS: age 65 or older, presence
of a B symptom at diagnosis, PS 2 to 4 at ASCT, more than 3Table 2
Univariate and Multivariate Analyses of Risk Factors for PFS and OS
Characteristic PFS
Univariate Multivariate
HR 95% CI P Value HR 95% CI
Age group (yr)
60-64 1.00 1.00
65-69 1.37 1.07-1.77 .014 1.32 1.02-1.71
70 1.35 .85-2.14 .202 1.58 .98-2.55
Sex
Female 1.00
Male 1.15 .89-1.48 .302
IPI at diagnosis
Low 1.00
Low-int 1.23 .78-1.94 .362
Int-high 1.24 .82-1.88 .317
High 1.73 1.14-2.64 .010
B symptoms at diagnosis
None 1.00 1.00
Present 1.45 1.11-1.90 .006 1.34 .99-1.80
PS at transplantation
0-1 1.00 1.00
2-4 2.10 1.50-2.93 <.001 1.65 1.16-2.36
Time from diagnosis to ASCT
Within 1 yr 1.00
Over 1 yr .77 .59-.99 .047
Date of ASCT
Before 2000 1.00
2000-2005 2.33 1.12-4.83 .023
After 2006 1.88 .92-3.82 .081
Date of diagnosis
Before Aug. 2003 1.00
After Sep.2003 1.21 .92-1.59 .183
High-dose regimen
MCEC based 1.00
MEAM based 1.27 .91-1.77 .165
LEED 1.52 1.04-2.22 .030
Others 1.11 .80-1.54 .540
No. of prior regimen
1-2 1.00
3 1.57 .94-2.63 .083
4 1.76 1.07-2.91 .027
Status at transplantation
CR 1.00 1.00
PR 1.36 .98-1.88 .065 1.30 .92-1.84
Not in remission 2.35 1.76-3.15 <.001 2.19 1.60-3.00
PFS indicates progression-free survival; OS, overall survival; HR, hazard ratio; 95%
mance status; ASCT, autologous stem cell transplantation; CR, complete respon
cyclophosphamide; MEAM, ranimustine, etoposide, cytarabine, and melphalan; LE
Bold indicates results that are statistically signiﬁcant.prior regimens, and response status at ASCT (Table 2).
Although age over 65 years was a signiﬁcant risk factor for
OS, the survival curve appeared to plateau, with a 2-year OSOS
Univariate Multivariate
P Value HR 95% CI P Value HR 95% CI P Value
1.00 1.00
.037 1.54 1.17-2.03 .002 1.45 1.09-1.94 .011
.058 1.65 1.02-2.66 .040 2.01 1.21-3.35 .007
1.00
1.15 .90-1.48 .250
1.00
1.68 .99-2.84 .055
1.56 .95-2.55 .081
2.15 1.31-3.54 .003
1.00 1.00
.053 1.52 1.14-2.03 .005 1.44 1.04-1.98 .027
1.00 1.00
.006 2.47 1.74-3.49 <.001 1.69 1.15-2.48 .007
1.00
.69 .52-.92 .010
1.00
1.78 .89-3.55 .103
1.70 .87-3.32 .122
1.00
1.20 .89-1.61 .227
1.00
1.26 .87-1.82 .213
1.49 .99-2.26 .057
1.07 .75-1.53 .698
1.00
1.92 1.08-3.43 .027 1.84 1.02-3.32 .043
2.16 1.20-3.89 .010 1.86 1.01-3.43 .047
1.00 1.00
.144 1.74 1.20-2.51 .003 1.53 1.01-2.32 .043
<.001 3.00 2.16-4.17 <.001 2.60 1.82-3.73 <.001
CI, 95% conﬁdence interval; IPI, international prognostic index; PS, perfor-
se; PR, partial response; MCEC, ranimustine, carboplatin, etoposide, and
ED, cyclophosphamide, etoposide, melphalan, and dexamethasone.
Figure 4. (A) Overall survival by age group and (B) overall survival by response status at transplantation. Abbreviation: CR, complete response; PR, partial response.
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70 years or older.
We attempted to evaluate the effect of rituximab in ﬁrst-
line treatment using a diagnosis date of before or after
September 2003, when rituximab was approved in Japan.
Results showed no signiﬁcant difference between groups in
either PFS or OS (Table 2).
DISCUSSION
The outcome in patients with relapsed/refractory DLBCL
who are unable to proceed to ASCT is very poor, with
essentially no chance of prolonged remission [19]. In this
study, we showed a relatively favorable outcome in elderly
patients who had relapsed or were refractory to ﬁrst-line
treatment and had received ASCT. According to the prior
study by the EBMT, the survival rate of elderly patients with
DLBCL who received ASCT was even higher than in our study
(EBMTstudy: 3-year PFS and OS of 51% and 60%, respectively)
[11]. However, this difference in the survival rate can be
explained by the difference in the patient characteristics, as
we excluded patients who received ASCT as consolidation
therapy for ﬁrst-line treatment. We restricted our analysis to
relapsed/refractory patients and included more refractory
patients than in the EBMT study (35% versus 6%). Insufﬁcient
response to chemotherapy before ASCT is the most predic-
tive factor of a poor prognosis. Even in elderly patients who
were not in remission at ASCT, however, 2-year OS in our
study was 41.6%. This ﬁnding suggests that ASCT might be
feasible not only for the relapsed but also for the refractory
elderly patients over 60 years old. Nevertheless, the efﬁcacy
of ASCT in elderly patients with relapsed/refractory DLBCL
needs to be investigated in prospective clinical studies.
The early NRM rate in our studywas 4.1% at day 100, which
is similar to the rate from the EBMT (4.4%) and appears to be
lower than those reported in other earlier studies [11,20,21].
This lower NRM may reﬂect the better selection of patients
able to proceed to ASCT and recent advances in supportive
therapies. Although NRM in elderly patients appears to be
decreasing, NRM in the EBMTstudywas signiﬁcantly higher in
elderly than in younger patients (NRM at 1 year:  60 years,
8.7%; < 60 years, 4.7%; P ¼ .002). Within the elderly popula-
tion, however, our study showed that age alone was not a
signiﬁcant risk factor for NRM, even in the population 70 years
and older. With regard to the risk factors of NRM, the EBMT
study reported that ages 60 years or over, 2 or more lines oftherapy prior to ASCT, poor PS at ASCT, and refractory disease
at ASCT were signiﬁcantly associated with NRM. We failed to
conﬁrm the predictive signiﬁcance of these factors, suggesting
that NRM is more related to the comorbidities and that the
prediction of NRM prior to the ASCT is difﬁcult in elderly
populations. Wildes et al. reported that comorbidities, but
not age itself, affect the outcome after ASCT, including NRM
[10]. Hematopoietic cell transplantationespeciﬁc comorbidity
index has been shown to have a prognostic value for alloge-
neic transplantation [22,23]. Although the clinical value of
comprehensive geriatric assessment has not beenwell shown
in the hematopoietic transplantation, comprehensive geriatric
assessment would be useful to identify the elderly patients
with DLBCL who can beneﬁt from curative approach [24].
Unfortunately, information to evaluate these indexes is not
available in the registry data of Japan Society for Hemato-
poietic Cell Transplantation, so we were not able to assess the
clinical value of them. These indexes will be useful in deﬁning
eligibility criteria for ASCT, and should be particularly evalu-
ated in elderly patients.
Data about differences in HDC are scarce, and thus a
“standard” HDC for ASCT has yet to be established.
Commonly used HDC include BEAM and CBV (cyclophos-
phamide, carmustine, etoposide), whereas a relatively small
proportion of patients undergo a TBI conditioning regimen
[11,25,26]. A previous study suggested that rates of second-
ary myelodysplastic syndrome/acute myeloid leukemia and
other long-term toxicities were lower with HDC without TBI
[27], and many clinicians accordingly favor chemotherapy-
only regimens as a standard approach, particularly for
elderly populations. In Japan, 2 major HDC regimens for
ASCT, other than theMEAM regimen, are the MCEC and LEED
regimens. HDC regimens appear to differ in their intensity
and toxicity proﬁles. In our study, a difference in HDC might
have affected NRM. A signiﬁcantly higher proportion of
elderly patients ages 70 years or older received an LEED
regimen, which was associated with signiﬁcantly lower NRM
but was associated with lower PFS thanMEAM andMCEC. As
a consequence, the LEED regimen showed no signiﬁcant
difference with MEAM and MCEC in OS, after adjustment for
other risk factors. Less intensive regimens, such as LEED, may
have a potential to increase the number of candidates for
ASCT among elderly patients who were thought to be ineli-
gible to other HDCs, which would in turn improve the out-
comes of elderly patients with relapse/refractory DLBCL.
D. Chihara et al. / Biol Blood Marrow Transplant 20 (2014) 684e689 689Although we showed a relatively favorable result for ASCT
in elderly patients, indications for and implementation of this
procedure should be carefully considered individually and
reserved for a selected population. Because of the retro-
spective nature of this study using a database of patients who
underwent transplantation, we were able to evaluate the
patients who underwent ASCT but were not able to evaluate
the whole picture of elderly patients with relapsed/refractory
DLBCL. It is important to evaluate the patients who intended
to undergo ASCT but failed during the salvage treatment.
Even now, this procedure will have only a limited impact on
outcomes in the overall population of patients with relapsed/
refractory DLBCL, because the proportion of elderly patients
who can proceed to ASCT is limited [19]. To increase the
number of candidates for therapy with curative intent, future
efforts should include improving salvage therapy to increase
response rate, evaluating the value of the comorbidity index
in detecting candidates for ASCT, improving the rate of suc-
cessful stem cell mobilization, and optimizing HDC for spe-
ciﬁc risk groups, such as those ages 70 years or older.
In conclusion, this study showed that ASCT is feasible for
selected population of elderly patients with relapsed/re-
fractory DLBCL and it confers prolonged survival, even those
older than 70 years or not in remission at ASCT. Nevertheless,
the efﬁcacy of ASCT for elderly patients with relapsed/re-
fractory DLBCL needs to be investigated in a prospective
clinical study. The lack of a signiﬁcant difference in NRM
among elderly patients indicates that age alone is not a
contraindication to salvage therapy with ASCT. Decision
making on eligibility for ASCT should be individualized.
Further investigation to identify a subset of elderly patients
who carry a high risk of treatment-related morbidity or
mortality is warranted.
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